Holen Sie sich die Stockscreener-App
48.01
1.24%
0.59
Vorhandelsmarkt:
48.24
0.23
+0.48%
Schlusskurs vom Vortag:
$47.42
Offen:
$47.43
24-Stunden-Volumen:
2.32M
Relative Volume:
0.74
Marktkapitalisierung:
$9.09B
Einnahmen:
$2.83B
Nettoeinkommen (Verlust:
$-1.02B
KGV:
-8.7132
EPS:
-5.51
Netto-Cashflow:
$194.14M
1W Leistung:
+4.12%
1M Leistung:
+0.52%
6M Leistung:
+1.27%
1J Leistung:
-22.18%
1-Tages-Spanne:
$47.28
$48.41
1-Wochen-Bereich:
$46.16
$48.41
52-Wochen-Spanne:
$38.81
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Firmenname
Exact Sciences Corp
Sektor
Branche
Telefon
608-284-5700
Adresse
5505 ENDEAVOR LANE, MADISON, WI
Vergleichen Sie EXAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
48.01 | 8.98B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
487.53 | 186.06B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
203.79 | 147.38B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
639.45 | 51.77B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
125.21 | 35.62B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
183.74 | 32.44B | 15.70B | 1.24B | 2.01B | 6.91 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-01-02 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-08-02 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Hochstufung | Craig Hallum | Hold → Buy |
| 2023-05-05 | Eingeleitet | UBS | Neutral |
| 2023-03-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-02-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-03 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Bestätigt | BTIG Research | Buy |
| 2021-07-29 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-29 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-29 | Bestätigt | Stifel | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Strong Buy |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-29 | Herabstufung | UBS | Buy → Neutral |
| 2020-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-02 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-10 | Fortgesetzt | BTIG Research | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Dougherty & Company | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-17 | Bestätigt | BofA/Merrill | Buy |
| 2019-10-01 | Fortgesetzt | Craig Hallum | Buy |
| 2019-09-26 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-26 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-09-05 | Fortgesetzt | The Benchmark Company | Hold |
| 2018-08-13 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-01-29 | Eingeleitet | Goldman | Neutral |
| 2018-01-08 | Bestätigt | The Benchmark Company | Buy |
| 2017-11-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Herabstufung | BTIG Research | Buy → Neutral |
Alle ansehen
Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten
Analyzing drawdowns of Exact Sciences Corporation with statistical toolsWeekly Stock Analysis & Community Consensus Picks - Newser
How to escape a deep drawdown in Exact Sciences CorporationForecast Cut & AI Driven Stock Movement Reports - Newser
Volume spikes in Exact Sciences Corporation stock – what they meanRate Cut & Low Risk Growth Stock Ideas - Newser
Can Exact Sciences Corporation be the next market leaderJuly 2025 EndofMonth & Fast Momentum Stock Entry Tips - خودرو بانک
Evaluating Exact Sciences Corporation with trendline analysisJuly 2025 Price Swings & Community Trade Idea Sharing Platform - Newser
Using data tools to time your Exact Sciences Corporation exitQuarterly Portfolio Report & Weekly Chart Analysis and Guides - Newser
Will Exact Sciences Corporation stock go up soonJuly 2025 Final Week & Free Weekly Chart Analysis and Trade Guides - Newser
Should I buy Exact Sciences Corporation stock nowJuly 2025 Drop Watch & Detailed Earnings Play Alerts - خودرو بانک
Will Exact Sciences Corporation outperform the marketJuly 2025 Opening Moves & Low Risk Investment Opportunities - Newser
What are the future prospects of Exact Sciences CorporationJuly 2025 Earnings & Safe Capital Allocation Plans - خودرو بانک
Developing predictive dashboards with Exact Sciences Corporation data2025 Top Gainers & Technical Confirmation Trade Alerts - Newser
How to read the order book for Exact Sciences CorporationTreasury Yields & AI Powered Market Entry Strategies - Newser
Is Exact Sciences Corporation stock forming a cup and handle2025 Bull vs Bear & Weekly Market Pulse Alerts - خودرو بانک
How Record Q2 Results and a New US$150 Million Savings Plan at Exact Sciences (EXAS) Have Changed Its Investment Story - Yahoo Finance
Exact Sciences Corporation’s volatility index tracking explained2025 Price Momentum & Expert Approved Trade Ideas - Newser
Is Exact Sciences Corporation stock entering bullish territoryJuly 2025 Action & Weekly Return Optimization Alerts - Newser
Applying Wyckoff theory to Exact Sciences Corporation stockWeekly Loss Report & Risk Managed Investment Strategies - Newser
Will breakout in Exact Sciences Corporation lead to full recoveryQuarterly Earnings Report & Long Hold Capital Preservation Plans - Newser
Real time scanner hits for Exact Sciences Corporation explainedJuly 2025 Selloffs & Consistent Income Trade Ideas - Newser
Historical volatility pattern of Exact Sciences Corporation visualized2025 Winners & Losers & Long-Term Growth Plans - Newser
Earnings visualization tools for Exact Sciences CorporationGap Up & Free High Accuracy Swing Entry Alerts - Newser
Combining price and volume data for Exact Sciences Corporation2025 Short Interest & Real-Time Volume Spike Alerts - Newser
Technical analysis overview for Exact Sciences Corporation stockMarket Performance Recap & Consistent Profit Alerts - Newser
Jefferies Reiterates a Buy Rating on Exact Sciences Corporation (EXAS) - Yahoo Finance
Published on: 2025-08-30 20:46:39 - Newser
Is Exact Sciences Corporation showing signs of accumulationTrade Exit Summary & Daily Growth Stock Tips - Newser
Should you wait for a breakout in Exact Sciences CorporationWeekly Stock Report & Community Consensus Stock Picks - Newser
What indicators show strength in Exact Sciences CorporationTrade Risk Report & Free Expert Approved Momentum Trade Ideas - Newser
What’s next for Exact Sciences Corporation stock priceBuy Signal & Community Verified Trade Alerts - Newser
Will Exact Sciences Corporation benefit from rising consumer demandJuly 2025 Sentiment & High Conviction Investment Ideas - sundaytimes.kr
Can Exact Sciences Corporation recover in the next quarter2025 Price Action Summary & Verified Momentum Stock Ideas - Newser
Predicting Exact Sciences Corporation trend using moving averagesProduct Launch & Stepwise Entry/Exit Trade Alerts - Newser
Is Exact Sciences Corporation stock reversal real or fakeTrade Signal Summary & Risk Adjusted Buy and Sell Alerts - Newser
Is Exact Sciences Corporation stock a growth or value playIndex Update & Fast Exit/Entry Strategy Plans - Newser
Finanzdaten der Exact Sciences Corp-Aktie (EXAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):